Medication for Opioid Use Disorder: A National Survey of Primary Care Physicians
Authors: Emma E. McGinty, Elizabeth M. Stone, Alene Kennedy-Hendricks, Marcus A. Bachhuber, Colleen L. Barry
Journal: Annals of Internal Medicine (2020)

Letters21 July 2020Medication for Opioid Use Disorder: A National Survey of Primary Care PhysiciansEmma E. McGinty, PhD, MS, Elizabeth M. Stone, MS, Alene Kennedy-Hendricks, PhD, Marcus A. Bachhuber, MD, and Colleen L. Barry, PhD, MPPEmma E. McGinty, PhD, MSJohns Hopkins Bloomberg School of Public Health and Johns Hopkins Center for Mental Health and Addiction Policy Research, Baltimore, Maryland (E.E.M., E.M.S., A.K., C.L.B.), Elizabeth M. Stone, MSJohns Hopkins Bloomberg School of Public Health and Johns Hopkins Center for Mental Health and Addiction Policy Research, Baltimore, Maryland (E.E.M., E.M.S., A.K., C.L.B.), Alene Kennedy-Hendricks, PhDJohns Hopkins Bloomberg School of Public Health and Johns Hopkins Center for Mental Health and Addiction Policy Research, Baltimore, Maryland (E.E.M., E.M.S., A.K., C.L.B.), Marcus A. Bachhuber, MDSection of Community and Population Medicine, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana (M.A.B.), and Colleen L. Barry, PhD, MPPJohns Hopkins Bloomberg School of Public Health and Johns Hopkins Center for Mental Health and Addiction Policy Research, Baltimore, Maryland (E.E.M., E.M.S., A.K., C.L.B.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-3975 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: More than 65% of persons with opioid use disorder (OUD) in the United States do not receive any treatment, including recommended treatment with 1 of the following U.S. Food and Drug Administration–approved medications: buprenorphine; methadone; or injectable, extended-release naltrexone (1). Efforts to expand treatment with medication have included a strong focus on primary care physicians who can prescribe injectable, extended-release naltrexone and, after obtaining a waiver from the Drug Enforcement Administration, buprenorphine for OUD in the office setting (1). (Methadone for OUD can be dispensed only in specialty programs [1].)Objective: To conduct a national survey examining primary care ...References1. National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. National Academies Pr; 2019. Google Scholar2. Petterson S, McNellis R, Klink K, et al. The State of Primary Care in the United States. A Chartbook of Facts and Statistics. Robert Graham Center; 2018. Google Scholar3. Samet JH, Botticelli M, Bharel M. Methadone in primary care—one small step for Congress, one giant leap for addiction treatment. N Engl J Med. 2018;379:7-8. [PMID: 29972744] doi:10.1056/NEJMp1803982 CrossrefMedlineGoogle Scholar4. Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2019;76:229-30. [PMID: 30586140] doi:10.1001/jamapsychiatry.2018.3685 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Johns Hopkins Bloomberg School of Public Health and Johns Hopkins Center for Mental Health and Addiction Policy Research, Baltimore, Maryland (E.E.M., E.M.S., A.K., C.L.B.)Section of Community and Population Medicine, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana (M.A.B.)Financial Support: By a Johns Hopkins University Frontier Award to Dr. McGinty.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3975.Reproducible Research Statement: Study protocol and data set: Not available. Statistical code: Available from Dr. McGinty (e-mail, [email protected]edu).This article was published at Annals.org on 21 April 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA patient-centered nurse-supported primary care-based collaborative care program to treat opioid use disorder and depression: Design and protocol for the MI-CARE randomized controlled trialProject ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomesMultidisciplinary treatment of opioid use disorder in primary care using the collaborative care modelHealth professionals' attitudes toward medications for opioid use disorderOpioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practiceState Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician AssistantsDoes a Survivorship Model of Opioid Use Disorder Improve Public Stigma or Policy Support? A General Population Randomized ExperimentHow a Medication for Opioid Use Disorder Curriculum Translates into Experiences and Internal Medicine Residents' Understanding of Patients with Opioid Use DisorderTraining in Safe Opioid Prescribing and Treatment of Opioid Use Disorder in Internal Medicine Residencies: a National Survey of Program DirectorsThe Opioid Epidemic and the State of Stigma: A Pennsylvania Statewide SurveyMedicaid Managed Care: Access To Primary Care Providers Who Prescribe BuprenorphinePrimary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphineUse of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use DisorderEffect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Care ProfessionalsAdapting Palliative Care Skills to Provide Substance Use Disorder Treatment to Patients With Serious IllnessOpioid use disorder treatment in rural settings: The primary care perspectiveBuprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectoriesRacial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to usePrimary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional surveyReadiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative EvaluationIntegrating DATA 2000 waiver training into undergraduate medical education: The time is nowThe role of stigma in U.S. primary care physicians' treatment of opioid use disorderExpanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysisTraining Medical Students, Residents, and Fellows in Opioid Use Disorder TreatmentA systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorderFraming Science: How Opioid Research Is Presented in Online News Media 21 July 2020Volume 173, Issue 2Page: 160-162KeywordsDisclosureDrug administrationDrugsFoodForecastingMotivationOpioid addictionOpioid use disorderPrimary care physiciansQuestionnaires ePublished: 21 April 2020 Issue Published: 21 July 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...